Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
News|Slideshows|October 5, 2020
Common Comorbidities in Behçet Disease
Author(s)Leo Robert
Behçet disease has been found to co-occur with a variety of other conditions. Click through 8 concise reviews of the evidence in this slide show.
Advertisement
Behçet disease (BD), a multisystemic disorder that has numerous clinical manifestations throughout the body, also has been reported to occur concomitantly with a variety of other conditions.
Scroll through the slides below for concise reports on conditions that are likely to coexist with BD.
Advertisement
Related to this article
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.
Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.
An EHR-integrated tool matched manual CKD and cardiovascular risk assessments in 60 patients and showed promise for improving risk-based kidney care in primary care.
TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.
Advertisement
Advertisement
Trending on Patient Care Online
1
When Night Sweats Signal Something Other Than Menopause
2
New Schizophrenia Treatment Addresses Long-Standing LAI Barriers
3
4 FDA Decisions for Primary Care to Know from October 2026
4
New Study Finds Low Initiation, Persistence With Menopause Hormone Therapy
5